Efficacy of different doses of sugammadex after continuous infusion of rocuronium

Table 1 Demographic characteristics

Sugammadex (dose)	Group A (n = 16)		Group B (n = 16)		P-value
Age (yr)	43.6	(SD 12.01)	47.1	(SD 14.18)	0.46
Weight (kg)	65.5	(SD 11.22)	60.9	(SD 10.62)	0.25
Height (cm)	163.2	(SD 4.76)	160.1	(SD 5.91)	0.12
BMI (kg/m2)	24.1	(SD 3.56)	23.2	(SD 3.65)	0.47
Intervention (time-minute)	95.2	(SD 26.91)	94.7	(SD 30.02)	0.96
ASA (1-2)	1.4	(SD 0.51)	1.2	(SD 0.48)	0.28
ASA 1a	n = 9	(56.25%)	n = 12	(75.00%)	0.23

Analyzed by student t-test. Both groups are similar.

^aASA 1 is expressed as percentage of patients with an ASA index of 1 in its group and a Fisher exact test was executed. BMI: Body mass index; ASA: American Society of Anesthesiologists.

Table 2 Train-of-four ratio studies

	Group A (n = 14)		Group B (n = 14)
	Mean	Median	Mean	Median	Assumed calculated interval (increased of 0% to 50% of median in group B)	Estimated difference median by Hodges-Lehmann estimator	95%CI
TOF ratio 0.9	118.8	129	96.6	105	0 to 52.5	24	0 to 45	Differences not assumed
TOF ratio 0.8	96.7	101	80.1	82.5	0 to 43.7	18	-5 to 39	Assumed
TOF ratio 0.7	78.4	90	66.3	65	0 to 32.5	10	-10 to 35	Assumed

Based on the value of the median of TOF ratio in the Group B, an interval was calculated to establish the acceptable variation of the median values in the Group A (an increase from 0% to 50% respect Group B). The Hodges-Lehmann estimator was calculated for the differences between TOF ratio 0.7, 0.8 and 0.9 medians with their 95%CI. All values are expressed in seconds. If the Hodges-Lehmann 95%CI was contained in the 95%CI based on medians of the Group B, no statistical and clinical differences would be assumed. TOF: Train-of-four.

Table 3 Adverse events

Adverse events	Group A	Group B
Arterial hypertension	0%	0%
Arterial hypotension	0%	0%
Bradycardia	0%	0%
Cough	0%	0%
Headache	0%	0%
Nausea	6.20%	6.20%
Pain	6.20%	6.20%
Residual neuromuscular blocking	0%	0%
Vomiting	0%	0%
Others	0%	6.20%